AU2001266838A1 - Inhibitors of matriptase for the treatment of cancer - Google Patents
Inhibitors of matriptase for the treatment of cancerInfo
- Publication number
- AU2001266838A1 AU2001266838A1 AU2001266838A AU6683801A AU2001266838A1 AU 2001266838 A1 AU2001266838 A1 AU 2001266838A1 AU 2001266838 A AU2001266838 A AU 2001266838A AU 6683801 A AU6683801 A AU 6683801A AU 2001266838 A1 AU2001266838 A1 AU 2001266838A1
- Authority
- AU
- Australia
- Prior art keywords
- matriptase
- inhibitors
- cancer
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21307300P | 2000-06-21 | 2000-06-21 | |
US60/213,073 | 2000-06-21 | ||
PCT/US2001/018773 WO2001097794A2 (en) | 2000-06-21 | 2001-06-12 | Inhibitors of matriptase for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001266838A1 true AU2001266838A1 (en) | 2002-01-02 |
Family
ID=22793641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001266838A Abandoned AU2001266838A1 (en) | 2000-06-21 | 2001-06-12 | Inhibitors of matriptase for the treatment of cancer |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1355637A2 (en) |
AU (1) | AU2001266838A1 (en) |
WO (1) | WO2001097794A2 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6797504B1 (en) | 2000-09-08 | 2004-09-28 | Dendreon San Diego Llc | Inhibitors of serine protease activity of matriptase or MTSP1 |
US7157596B2 (en) | 2000-09-08 | 2007-01-02 | Dendreon Corporation | Inhibitors of serine protease activity of matriptase or MTSP1 |
DE50310038D1 (en) | 2002-03-11 | 2008-08-07 | Curacyte Ag | INGREDIENTS OF UROKINASE, THEIR PREPARATION AND USE |
US7939304B2 (en) | 2002-10-02 | 2011-05-10 | Catalyst Biosciences, Inc. | Mutant MT-SP1 proteases with altered substrate specificity or activity |
US7019019B2 (en) | 2002-12-23 | 2006-03-28 | Dendreon Corporation | Matriptase inhibitors and methods of use |
DE10301300B4 (en) | 2003-01-15 | 2009-07-16 | Curacyte Chemistry Gmbh | Use of acylated 4-amidino- and 4-guanidinobenzylamines for the inhibition of plasma kallikrein |
DE10322191B4 (en) | 2003-05-16 | 2014-02-27 | The Medicines Company (Leipzig) Gmbh | N-sulfonylated amino acid derivatives, process for their preparation and their use |
DE10342108A1 (en) | 2003-09-11 | 2005-04-14 | Curacyte Chemistry Gmbh | Basic substituted benzylamine analogs as coagulation factor Xa inhibitors, their preparation and use |
US7439226B2 (en) | 2003-09-30 | 2008-10-21 | The United States Of America As Represented By The Department Of Health And Human Services | Serine protease inhibitors |
CA2562729C (en) | 2004-04-12 | 2013-11-12 | Sandra Waugh Ruggles | Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1 |
KR101476458B1 (en) | 2006-07-05 | 2015-01-05 | 카탈리스트 바이오사이언시즈, 인코포레이티드 | Protease screening methods and proteases identified thereby |
DE102006050672A1 (en) | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | New glycylglycine derivatives with a benzylsulfonylamido group and an amidino-organylamido group at the opposite chain ends, used in drugs for reducing loss of blood, e.g. in operations |
DE102008007440A1 (en) * | 2008-02-01 | 2009-08-13 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg | Amino acid derivatives as drugs |
US8722930B2 (en) | 2009-05-18 | 2014-05-13 | Orion Corporation | Protease inhibitors |
US10175238B2 (en) * | 2014-05-13 | 2019-01-08 | Georgetown University | Markers for abnormal cells |
EP3558938A4 (en) * | 2016-12-22 | 2020-08-19 | Verlyx Pharma Inc. | Amidine substituted analogues and uses thereof |
CN112996529A (en) * | 2018-10-02 | 2021-06-18 | 迪斯克医药公司 | Matriptase 2 inhibitor and application thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH525896A (en) * | 1961-09-11 | 1972-07-31 | Wander Ag Dr A | Cyclic bis-amidine cpds - esp useful as tuberculostats |
AU4432597A (en) * | 1996-09-25 | 1998-04-17 | Regents Of The University Of California, The | Methods of using agmatine to reduce intracellular polyamine levels and to inhibit inducible nitric oxide synthase |
AU4679900A (en) * | 1999-04-30 | 2000-11-17 | Slil Biomedical Corporation | Conformationally restricted polyamine analogs as disease therapies |
DE60042245D1 (en) * | 1999-11-16 | 2009-07-02 | Oncozyme Pharma Inc | PENTAMIDINE FOR THE TREATMENT OF CANCER |
DE19955476A1 (en) * | 1999-11-18 | 2001-05-23 | Boehringer Ingelheim Pharma | Bis-basic compounds as tryptase inhibitors, process for their preparation and their use as medicaments |
-
2001
- 2001-06-12 EP EP01944426A patent/EP1355637A2/en not_active Withdrawn
- 2001-06-12 AU AU2001266838A patent/AU2001266838A1/en not_active Abandoned
- 2001-06-12 WO PCT/US2001/018773 patent/WO2001097794A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2001097794A3 (en) | 2003-08-21 |
EP1355637A2 (en) | 2003-10-29 |
WO2001097794A2 (en) | 2001-12-27 |
WO2001097794A8 (en) | 2003-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002339157A1 (en) | Inhibitors of the notch signalling pathway for use in the treatment of cancer | |
AU2002223827A1 (en) | Well treatment | |
AU2002219472A1 (en) | Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens | |
AU2002226069A1 (en) | Compositions comprising temozolomide and thalidomide and methods for the treatment of cancer | |
AU6147401A (en) | Compositions and methods for the treatment of cancer | |
IL152754A0 (en) | Quinazoline derivatives for the treatment of tumours | |
AU2001266068A1 (en) | Treatment of mineral substrates | |
AU2001227966A1 (en) | Methods for treating tumors | |
AU2002328952A1 (en) | Irinotecan for treatment of cancer | |
AU2001249626A1 (en) | Cathepsin inhibitors in cancer treatment | |
AU2002340168A1 (en) | Treatment of prostate cancer by inhibitors of ncam2 | |
AU2001266838A1 (en) | Inhibitors of matriptase for the treatment of cancer | |
AUPQ923100A0 (en) | Treatment of prostate cancer | |
EP1176964B8 (en) | Uses of et743 for treating cancer | |
AU2002248269A1 (en) | Use of p38 inhibitors for the treatment of inflammation-enhanced cough | |
AU2000258650A1 (en) | 2-piperidone compounds for the treatment of cancer | |
AU2001228703A1 (en) | Use of cox-2 inhibitors for the treatment of constipation | |
AU2002217866A1 (en) | Geldanamycin derivatives useful for the treatment of cancer | |
AU2001290165A1 (en) | Components of canola for the treatment of cancer | |
AU8322401A (en) | Indole compounds useful for the treatment of cancer | |
AU2001293891A1 (en) | New combination for the treatment of asthma | |
AU2002217447A1 (en) | Apparatus for lipolysis for aesthetic treatment | |
AU2001232060A1 (en) | Use of cyp1b1 inhibitors for treating cancer | |
AU2001253836A1 (en) | Method of treating cancer | |
AU2001214116A1 (en) | Novel paclitaxel derivatives for the treatment of cancer |